ECHS1 Inhibitors
ECHS1 inhibitors, also known as Enoyl-CoA Hydratase Short Chain 1 inhibitors, belong to a specific class of chemical compounds designed to target and modulate the activity of the ECHS1 enzyme. ECHS1, an abbreviation for Enoyl-CoA Hydratase Short Chain 1, is a crucial enzyme involved in fatty acid metabolism within the mitochondria of eukaryotic cells. This enzyme plays a pivotal role in the beta-oxidation pathway, which is responsible for breaking down fatty acids to generate energy. ECHS1 catalyzes the hydration of crotonyl-CoA to beta-hydroxybutyryl-CoA, a key step in the breakdown of short-chain fatty acids.
IECHS1 are designed to interfere with the enzyme's normal function, disrupting the conversion of crotonyl-CoA to beta-hydroxybutyryl-CoA. This disruption can lead to a buildup of crotonyl-CoA and a subsequent disturbance in fatty acid metabolism. The development of ECHS1 inhibitors is of interest in various research areas, as they can be valuable tools for studying the role of ECHS1 in metabolism and related biological processes. Additionally, these inhibitors may have potential applications in many fields, such as in elucidating the underlying mechanisms of metabolic diseases or exploring novel strategies for altering cellular energy metabolism.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
rac Perhexiline Maleate | 6724-53-4 | sc-460183 | 10 mg | $188.00 | ||
Inhibits mitochondrial carnitine palmitoyltransferase-1 (CPT1), potentially reducing substrate availability for ECHS1. | ||||||
4-Hydroxy-L-phenylglycine | 32462-30-9 | sc-254680A sc-254680 | 5 g 10 g | $82.00 $109.00 | ||
Inhibits CPT1, potentially leading to reduced fatty acid transport into mitochondria and therefore less substrate for ECHS1. | ||||||
(+)-Etomoxir sodium salt | 828934-41-4 | sc-215009 sc-215009A | 5 mg 25 mg | $151.00 $506.00 | 3 | |
Irreversible inhibitor of CPT1, could decrease the amount of fatty acids entering beta-oxidation and thus ECHS1 activity. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Endogenous molecule which inhibits CPT1, could indirectly reduce ECHS1 activity by limiting its substrates. | ||||||
1-(2,3,4-Trimethoxybenzyl)piperazine | 5011-34-7 | sc-297236 | 500 mg | $374.00 | ||
Partially inhibits fatty acid oxidation, potentially decreasing the availability of ECHS1 substrates. | ||||||
Ranolazine | 95635-55-5 | sc-212769 | 1 g | $109.00 | 3 | |
Limits fatty acid beta-oxidation, potentially reducing ECHS1 activity by decreasing substrate flow. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
Known to disrupt mitochondrial beta-oxidation, possibly affecting ECHS1 activity. | ||||||
Fenofibrate | 49562-28-9 | sc-204751 | 5 g | $41.00 | 9 | |
Activates peroxisome proliferator-activated receptor alpha (PPARα), potentially upregulating proteins that compete with ECHS1. | ||||||
Gemfibrozil | 25812-30-0 | sc-204764 sc-204764A | 5 g 25 g | $66.00 $267.00 | 2 | |
Similar to fenofibrate, may indirectly affect ECHS1 by modulating fatty acid metabolism. | ||||||
Meldonium | 76144-81-5 | sc-207887 | 100 mg | $455.00 | 1 | |
Inhibits gamma-butyrobetaine hydroxylase, potentially reducing carnitine biosynthesis and subsequent substrate availability for ECHS1. | ||||||